SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2142608

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2142608

High Flow Nasal Cannula Market by Product (Systems, Consumables & Accessories (Humidifiers, Interfaces)), Patient Type (Neonatal & Pediatric), Application (Acute Respiratory Failure, COPD), End User (Hospitals), & Region - Global Forecast to 2031

PUBLISHED:
PAGES: 292 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The high-flow nasal cannula (HFNC) market is projected to reach USD 1.44 billion by 2031 from USD 0.94 billion in 2026, at a CAGR of 8.9% during the forecast period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Patient type, Application, End User, and Region
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The HFNC market is experiencing growth due to the increasing burden of acute and chronic respiratory disorders, rising cases of acute hypoxemic respiratory failure, and growing demand for non-invasive respiratory support. HFNC provides more reliable oxygen delivery along with heated and humidified gas, improved oxygenation, reduced work of breathing, upper-airway dead-space washout, and enhanced secretion clearance. Its greater patient comfort and tolerance compared with conventional oxygen therapy and certain forms of NIV also support wider clinical adoption. In addition, the expansion of HFNC applications across intensive care units, emergency departments, post-extubation care, pre-oxygenation before intubation, perioperative management, bronchoscopy, and during breaks from NIV or CPAP is contributing to market growth. Increasing clinical acceptance and the availability of HFNC systems for neonatal, pediatric, and adult patients are further broadening its use across healthcare settings.

High Flow Nasal Cannula Market - IMG1

"By application, the acute respiratory failure segment is estimated to account for the largest share of the high-flow nasal cannula market."

Acute respiratory failure holds the largest share of the high-flow nasal cannula (HFNC) market by application, primarily due to the increasing use of HFNC as a non-invasive respiratory support option for patients with acute hypoxemic respiratory failure. HFNC can deliver high flows of heated and humidified oxygen, helping improve oxygenation, reduce work of breathing, and support patients with significant respiratory distress. Clinical guidelines recommend HFNC over conventional oxygen therapy in adults with acute hypoxemic respiratory failure, supporting its widespread adoption in intensive care units, emergency departments, and other acute-care settings. The growing incidence of pneumonia, acute respiratory distress, pulmonary infections, and exacerbations of underlying cardiopulmonary conditions further contributes to demand for HFNC in this application. In addition, the increasing preference for non-invasive respiratory support and the potential to reduce or delay the need for invasive ventilation in appropriate patients are supporting the continued expansion of this segment.

"By end user, the hospitals segment is estimated to account for the largest share of the high-flow nasal cannula market."

Hospitals hold the largest share of the high-flow nasal cannula (HFNC) market by end user, primarily due to the widespread use of HFNC in intensive care units, emergency departments, respiratory wards, and post-operative care. Hospitals manage a large volume of patients with acute hypoxemic respiratory failure and other conditions requiring advanced respiratory support, making them the primary setting for HFNC utilization. Clinical guidelines also support the use of HFNC in acute respiratory failure, particularly in critically ill patients who require close monitoring and timely escalation of respiratory support. Furthermore, the availability of specialized critical-care infrastructure, trained healthcare professionals, oxygen supply systems, and monitoring equipment enables hospitals to support wider and more frequent HFNC use. The expanding application of HFNC for post-extubation support, pre-oxygenation, perioperative care, and emergency respiratory management is further contributing to the segment's leading position.

"The US is expected to witness the highest CAGR in the high-flow nasal cannula market in North America."

The US is expected to grow at the highest rate within the North American high-flow nasal cannula (HFNC) market, supported by the country's advanced healthcare infrastructure, high prevalence of respiratory disorders, and widespread adoption of non-invasive respiratory support technologies. HFNC is extensively used across US hospitals for acute hypoxemic respiratory failure, emergency care, intensive care, and post-extubation support. A US survey found that HFNC was used in responding hospitals, with particularly high utilization in emergency departments, highlighting its strong clinical adoption. The presence of established HFNC manufacturers and continued regulatory clearances also supports market expansion. For example, the US FDA has cleared HFNC systems from manufacturers such as Vapotherm and Fisher & Paykel Healthcare, expanding the availability of advanced HFNC technologies in the country. In addition, growing clinical evidence, increasing use beyond intensive care units, and continued expansion of HFNC applications across acute and respiratory care settings are expected to further drive US market growth.

A breakdown of the primary participants (supply-side) for the high-flow nasal cannula market referred to in this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
  • By Designation: C-level-45%, Director Level-35%, and Others-20%
  • By Region: North America-27%, Europe-25%, Asia Pacific-30%, Latin America- 8%, Middle East & Africa-10%.

Prominent players in the high-flow nasal cannula market include Fisher & Paykel Healthcare Limited (New Zealand), Vapotherm (US), ResMed (US), Hamilton Medical AG (Switzerland), and Dragerwerk AG & Co. KGaA (Germany).

Research Coverage:

The report analyzes the high-flow nasal cannula market and aims at estimating the market size and future growth potential of this market based on various segments such as product, patient type, application, end user and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall high-flow nasal cannula market. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

  • Analysis of key drivers (" Growing burden of acute and chronic respiratory diseases, Increasing preference for non-invasive respiratory support, Increasing HFNC utilization in ICUs and emergency departments, High burden of premature births and neonatal respiratory complications) restraints (High acquisition and recurring consumable costs, High medical oxygen requirement) opportunities (Expansion of HFNC into home and long-term care settings, Large untapped opportunity in emerging economies, Development of compact and portable high-flow systems) and challenges (Early identification of HFNC treatment failure, Need for continuous clinical monitoring and trained personnel).
  • Market Penetration: It includes extensive information on products offered by the major players in the high-flow nasal cannula market. The report includes various segments, including product, patient type, application, end user, and region.
  • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the high-flow nasal cannula market.
  • Market Development: Thorough knowledge and analysis of the profitable rising markets by product, patient type, application, end user, and region.
  • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the high-flow nasal cannula market.
  • Competitive Assessment: Thorough evaluation of the market shares, growth plans, product offerings, and capacities of the major competitors in the high-flow nasal cannula market.
Show more
Product Code: MD 10617

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 SEGMENTS CONSIDERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 HIGH FLOW NASAL CANNULA MARKET OVERVIEW
  • 3.2 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT AND COUNTRY (2025)
  • 3.3 HIGH FLOW NASAL CANNULA MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (2025)
  • 3.4 HIGH FLOW NASAL CANNULA MARKET, BY REGION (2024-2031)
  • 3.5 HIGH FLOW NASAL CANNULA MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Growing burden of acute and chronic respiratory diseases
      • 4.2.1.2 Increasing preference for non-invasive respiratory support
      • 4.2.1.3 Increasing HFNC utilization in ICUs and emergency departments
      • 4.2.1.4 High burden of premature births and neonatal respiratory complications
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High acquisition and recurring consumable costs
      • 4.2.2.2 High medical oxygen requirement
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion of HFNC into home and long-term care settings
      • 4.2.3.2 Large untapped opportunity in emerging economies
      • 4.2.3.3 Development of compact and portable high-flow systems
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Early identification of HFNC treatment failure
      • 4.2.4.2 Need for continuous clinical monitoring and trained personnel
  • 4.3 UNMET NEEDS AND WHITE SPACES
    • 4.3.1 UNMET NEEDS IN HIGH FLOW NASAL CANNULA MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKET
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN VENTILATORS INDUSTRY
    • 5.2.4 TRENDS IN OXYGEN THERAPY EQUIPMENT INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS (2023-2025)
    • 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCT, BY KEY PLAYER (2025)
    • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
  • 5.7 TRADE DATA ANALYSIS
    • 5.7.1 IMPORT DATA FOR HIGH FLOW NASAL CANNULA PRODUCTS (HS CODE 9019)
    • 5.7.2 EXPORT DATA FOR HIGH FLOW NASAL CANNULA PRODUCTS (HS CODE 9019)
  • 5.8 KEY CONFERENCES AND EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.10 HIGH FLOW NASAL CANNULA MARKET, INVESTMENT AND FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 CASE STUDY 1: HIGH-FLOW NASAL CANNULA FOR HYPOXEMIC RESPIRATORY FAILURE
    • 5.11.2 CASE STUDY 2: HFNC OXYGEN THERAPY OUTSIDE THE ICU
    • 5.11.3 CASE STUDY 3: HIGH-FLOW NASAL OXYGEN FOR COVID-19-ASSOCIATED ACUTE RESPIRATORY FAILURE
  • 5.12 IMPACT OF 2025 US TARIFF - OVERVIEW
    • 5.12.1 INTRODUCTION
    • 5.12.2 KEY TARIFF RATES
  • 5.13 PRICE IMPACT ANALYSIS
    • 5.13.1 IMPACT ON COUNTRY/REGION
      • 5.13.1.1 US
      • 5.13.1.2 Europe
      • 5.13.1.3 Asia Pacific
  • 5.14 IMPACT ON END USER INDUSTRIES

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 HIGH-FLOW GAS GENERATION
    • 6.1.2 AIR-OXYGEN BLENDING
    • 6.1.3 TURBINE/BLOWER-BASED FLOW GENERATION
    • 6.1.4 COMPLEMENTARY TECHNOLOGIES
      • 6.1.4.1 Humidification chamber technology
      • 6.1.4.2 Heated-wire circuit technology
    • 6.1.5 ADJACENT TECHNOLOGIES
      • 6.1.5.1 Conventional oxygen therapy (COT)
  • 6.2 TECHNOLOGY/PRODUCT ROADMAP
    • 6.2.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
    • 6.2.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
    • 6.2.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
  • 6.3 PATENT ANALYSIS
  • 6.4 FUTURE APPLICATIONS OF HIGH FLOW NASAL CANNULA
  • 6.5 IMPACT OF AI/GEN AI ON HIGH FLOW NASAL CANNULA MARKET
    • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.5.2 BEST PRACTICES IN HIGH FLOW NASAL CANNULA FOR AI MODEL DEVELOPMENT AND DEPLOYMENT
    • 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN THE HIGH FLOW NASAL CANNULA MARKET
    • 6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.5.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN HIGH FLOW NASAL CANNULA MARKET

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
        • 7.1.2.1.1 US
        • 7.1.2.1.2 Canada
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
        • 7.1.2.3.1 Japan
        • 7.1.2.3.2 China
        • 7.1.2.3.3 India
    • 7.1.3 INDUSTRY STANDARDS
  • 7.2 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DDECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 SOURCE: INTERVIEW WITH EXPERTS AND MARKETSANDMARKETS ANALYSIS
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 HFNC SYSTEMS/EQUIPMENT
  • 9.3 CONSUMABLES AND ACCESSORIES
    • 9.3.1 HUMIDIFIERS
      • 9.3.1.1 Increasing recognition of heated humidification in high-flow therapy to drive adoption of HFNC-compatible humidifiers
    • 9.3.2 NASAL CANNULAS/INTERFACES
      • 9.3.2.1 Growing preference for comfortable and patient-specific interfaces to support HFNC adoption
    • 9.3.3 BREATHING CIRCUITS/SETS
      • 9.3.3.1 Rising use of disposable patient circuits and improved circuit designs to support recurring market demand
    • 9.3.4 HUMIDIFICATION CHAMBERS
      • 9.3.4.1 Increasing demand for efficient water management and humidification delivery to support humidification chamber adoption
    • 9.3.5 OTHER CONSUMABLES & ACCESSORIES
      • 9.3.5.1 Expansion of HFNC system configurations to increase demand for complementary accessories

10 HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 ACUTE RESPIRATORY FAILURE
    • 10.2.1 INCREASING ADOPTION OF HFNC AS NONINVASIVE RESPIRATORY-SUPPORT STRATEGY FOR ACUTE HYPOXEMIC RESPIRATORY FAILURE TO DRIVE MARKET GROWTH
  • 10.3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    • 10.3.1 GROWING EVIDENCE FOR LONG-TERM AND ACUTE USE OF HFNC IN COPD TO SUPPORT MARKET EXPANSION
  • 10.4 ACUTE HEART FAILURE
    • 10.4.1 INCREASING CLINICAL EVALUATION OF HFNC FOR HYPOXEMIA ASSOCIATED WITH ACUTE HEART FAILURE TO CREATE GROWTH OPPORTUNITIES
  • 10.5 OTHER APPLICATIONS

11 HIGH FLOW NASAL CANNULA MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS
    • 11.2.1 INCREASING ADOPTION OF HFNC IN EMERGENCY, INTENSIVE-CARE, NEONATAL, AND GENERAL HOSPITAL SETTINGS TO MAINTAIN HOSPITAL DOMINANCE
  • 11.3 HOME CARE SETTINGS
    • 11.3.1 EXPANSION OF LONG-TERM HFNC THERAPY INTO HOME SETTING TO CREATE NEW GROWTH OPPORTUNITIES
  • 11.4 LONG-TERM CARE FACILITIES
    • 11.4.1 GROWING NEED FOR NON-INVASIVE RESPIRATORY SUPPORT IN CHRONIC RESPIRATORY DISEASE TO SUPPORT HFNC ADOPTION IN LONG-TERM CARE
  • 11.5 OTHER END USERS

12 HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE

  • 12.1 INTRODUCTION
  • 12.2 NEONATAL & PEDIATRIC (0-17YRS)
    • 12.2.1 INCREASING USE OF HFNC FOR NEONATAL AND PEDIATRIC RESPIRATORY SUPPORT TO DRIVE MARKET GROWTH
  • 12.3 ADULT (18-64)
    • 12.3.1 INCREASING PREVALENCE OF ACUTE RESPIRATORY FAILURE AND BROADER CLINICAL ADOPTION OF HFNC TO DRIVE THE ADULT SEGMENT
  • 12.4 GERIATRIC (65+)
    • 12.4.1 RISING BURDEN OF RESPIRATORY DISORDERS AMONG OLDER ADULTS TO SUPPORT HFNC ADOPTION IN GERIATRIC PATIENTS

13 HIGH FLOW NASAL CANNULA MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 US
      • 13.2.1.1 Large respiratory-care burden and preterm-birth population to support HFNC utilization
    • 13.2.2 CANADA
      • 13.2.2.1 Population aging and severe seasonal respiratory infections to drive demand
  • 13.3 EUROPE
    • 13.3.1 GERMANY
      • 13.3.1.1 Large hospital infrastructure and an aging population to sustain HFNC demand
    • 13.3.2 FRANCE
      • 13.3.2.1 Aging population and severe winter respiratory activity to support adoption
    • 13.3.3 UK
      • 13.3.3.1 High emergency respiratory admissions to propel market growth
    • 13.3.4 ITALY
      • 13.3.4.1 Rapid population aging to shift demand toward adult and geriatric HFNC applications
    • 13.3.5 SPAIN
      • 13.3.5.1 Increasing respiratory mortality to strengthen the requirement for advanced oxygen support
    • 13.3.6 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 JAPAN
      • 13.4.1.1 Exceptionally high elderly population to sustain respiratory-support demand
    • 13.4.2 CHINA
      • 13.4.2.1 Expanding hospital capacity and rapid aging to propel HFNC adoption
    • 13.4.3 INDIA
      • 13.4.3.1 Expansion of district-level critical-care infrastructure to widen addressable market
    • 13.4.4 AUSTRALIA
      • 13.4.4.1 High COPD-related hospital utilization and preterm births to support demand
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Transition to a super-aged society to increase respiratory-care requirements
    • 13.4.6 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 BRAZIL
      • 13.5.1.1 Rapid population aging and formal respiratory-care pathways to support market development
    • 13.5.2 MEXICO
      • 13.5.2.1 Tobacco exposure and a large hospital population to sustain respiratory-support demand
    • 13.5.3 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 GCC COUNTRIES
      • 13.6.1.1 Modern hospital infrastructure and chronic disease to support HFNC adoption
    • 13.6.2 REST OF MIDDLE EAST AND AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HIGH FLOW NASAL CANNULA MARKET
  • 14.3 REVENUE ANALYSIS, 2021-2025
  • 14.4 MARKET SHARE ANALYSIS, 2025
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 14.5.5.1 Company footprint
      • 14.5.5.2 Region footprint
      • 14.5.5.3 Product footprint
      • 14.5.5.4 Procedure footprint
      • 14.5.5.5 Application footprint
      • 14.5.5.6 End-user footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 DYNAMIC COMPANIES
    • 14.6.3 STARTING BLOCKS
    • 14.6.4 RESPONSIVE COMPANIES
    • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
  • 14.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 14.7.1 FINANCIAL METRICS
    • 14.7.2 COMPANY VALUATION
    • 14.7.3 BRAND/PRODUCT COMPARISON
  • 14.8 COMPETITIVE SCENARIO
    • 14.8.1 DEALS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 FISHER & PAYKEL HEALTHCARE LIMITED
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 MnM view
        • 15.1.1.3.1 Key strengths
        • 15.1.1.3.2 Strategic choices
        • 15.1.1.3.3 Weaknesses and competitive threats
    • 15.1.2 VAPOTHERM
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Deals
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Key strengths
        • 15.1.2.4.2 Strategic choices made
        • 15.1.2.4.3 Weaknesses and competitive threats
    • 15.1.3 RESMED INC.
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products offered
      • 15.1.3.3 MnM view
        • 15.1.3.3.1 Key strengths
        • 15.1.3.3.2 Strategic choices made
        • 15.1.3.3.3 Weaknesses and competitive threats
    • 15.1.4 HAMILTON MEDICAL
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products offered
      • 15.1.4.3 Recent developments
        • 15.1.4.3.1 Expansions
      • 15.1.4.4 MnM view
        • 15.1.4.4.1 Key strengths
        • 15.1.4.4.2 Strategic choices made
        • 15.1.4.4.3 Weaknesses and competitive threats
    • 15.1.5 DRAGERWERK AG & CO. KGAA
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products offered
      • 15.1.5.3 MnM view
        • 15.1.5.3.1 Key strengths
        • 15.1.5.3.2 Strategic choices made
        • 15.1.5.3.3 Weaknesses and competitive threats
    • 15.1.6 INSPIRATION HEALTHCARE GROUP PLC
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products offered
    • 15.1.7 MASIMO (SUBSIDIARY OF DANAHER CORPORATION)
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Deals
    • 15.1.8 VINCENT MEDICAL HOLDINGS LIMITED
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
    • 15.1.9 FLEXICARE (GROUP) LIMITED
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products offered
    • 15.1.10 MICOMME MEDICAL
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products offered
    • 15.1.11 BMC MEDICAL CO., LTD.
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
    • 15.1.12 EAKIN HEALTHCARE
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
    • 15.1.13 LOWENSTEIN MEDICAL SE & CO. KG
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products offered
    • 15.1.14 SHENZHEN COMEN MEDICAL INSTRUMENTS CO., LTD.
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products offered
    • 15.1.15 MEDLINE
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products offered
  • 15.2 OTHER PLAYERS
    • 15.2.1 INTERSURGICAL LTD
    • 15.2.2 RESPIRCARE MEDICAL
    • 15.2.3 GREAT GROUP MEDICAL CO., LTD.
    • 15.2.4 GALEMED CORPORATION
    • 15.2.5 SILMAG S.A.
    • 15.2.6 SALAERA LLC
    • 15.2.7 TELESAIR, INC.
    • 15.2.8 HEKA MEDICALS INDIA PVT. LTD.
    • 15.2.9 BESMED HEALTH BUSINESS CORP.
    • 15.2.10 CREATE BIOTECH CO., LTD.

16 RESEARCH METHODOLOGY

  • 16.1 RESEARCH DATA
    • 16.1.1 SECONDARY DATA
      • 16.1.1.1 Key data from secondary sources
    • 16.1.2 PRIMARY DATA
      • 16.1.2.1 Key data from primary sources
      • 16.1.2.2 Key industry insights
  • 16.2 MARKET SIZE ESTIMATION
    • 16.2.1 BOTTOM-UP APPROACH
    • 16.2.2 TOP-DOWN APPROACH
    • 16.2.3 BASE NUMBER ESTIMATION
  • 16.3 MARKET FORECAST APPROACH
  • 16.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 16.5 ASSUMPTIONS
    • 16.5.1 MARKET SHARE ASSUMPTIONS
  • 16.6 FACTOR ANALYSIS
  • 16.7 RISK ASSESSMENT
  • 16.8 METHODOLOGY-RELATED LIMITATIONS

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS
Show more
Product Code: MD 10617

List of Tables

  • TABLE 1 HIGH FLOW NASAL CANNULA MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 HIGH FLOW NASAL CANNULA MARKET: CURRENT UNMET NEEDS
  • TABLE 3 HIGH FLOW NASAL CANNULA MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 4 GDP PERCENTAGE CHANGE, BY KEY COUNTRIES, 2021-2030
  • TABLE 5 AVERAGE SELLING PRICE TREND OF HFNC SYSTEM, BY KEY PLAYER, 2025 (USD)
  • TABLE 6 AVERAGE PRICING TREND OF HIGH FLOW NASAL CANNULA, BY REGION, 2023-2025 (USD)
  • TABLE 7 IMPORT DATA FOR HIGH FLOW NASAL CANNULA PRODUCTS (HS CODE 9019), BY COUNTRY, 2021-2025 (USD THOUSANDS)
  • TABLE 8 EXPORT DATA FOR HIGH FLOW NASAL CANNULA PRODUCTS (HS CODE 9019), BY COUNTRY, 2021-2025 (USD THOUSANDS)
  • TABLE 9 HIGH FLOW NASAL CANNULA MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS (2026-2027)
  • TABLE 10 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 11 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR HIGH FLOW NASAL CANNULA
  • TABLE 12 HIGH FLOW NASAL CANNULA MARKET: CASE STUDIES RELATED TO AI IMPLEMENTATION
  • TABLE 13 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 US: CLASSIFICATION OF MEDICAL EQUIPMENT
  • TABLE 18 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 19 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 20 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 21 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 GLOBAL STANDARDS IN HIGH FLOW NASAL CANNULA MARKET
  • TABLE 24 CERTIFICATIONS, LABELING, ECO-STANDARDS IN HIGH FLOW NASAL CANNULA MARKET
  • TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • TABLE 26 KEY BUYING CRITERIA FOR HIGH FLOW NASAL CANNULA SYSTEMS
  • TABLE 27 HIGH FLOW NASAL CANNULA MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 28 HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 29 HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 30 HIGH FLOW NASAL CANNULA SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 31 HIGH FLOW NASAL CANNULA SYSTEMS MARKET, BY REGION, 2024-2031 (MILLION UNITS)
  • TABLE 32 HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 33 HUMIDIFIERS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 34 NASAL CANNULAS/INTERFACES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 35 BREATHING CIRCUITS/SETS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 HUMIDIFICATION CHAMBERS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 OTHER CONSUMABLES & ACCESSORIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION 2024-2031 (USD MILLION)
  • TABLE 39 HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, BY COUNTRY 2024-2031 (USD MILLION)
  • TABLE 40 HIGH FLOW NASAL CANNULA MARKET FOR ACUTE RESPIRATORY FAILURE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 HIGH FLOW NASAL CANNULA MARKET FOR COPD, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 HIGH FLOW NASAL CANNULA MARKET FOR ACUTE HEART FAILURE, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 HIGH FLOW NASAL CANNULA MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 45 HIGH FLOW NASAL CANNULA MARKET, BY END USER, BY COUNTRY 2024-2031 (USD MILLION)
  • TABLE 46 HIGH FLOW NASAL CANNULA MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 47 HIGH FLOW NASAL CANNULA MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 48 HIGH FLOW NASAL CANNULA MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 HIGH FLOW NASAL CANNULA MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE 2024-2031 (USD MILLION)
  • TABLE 51 HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, BY COUNTRY 2024-2031 (USD MILLION)
  • TABLE 52 HIGH FLOW NASAL CANNULA MARKET FOR NEONATAL & PEDIATRIC (0-17YRS), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 HIGH FLOW NASAL CANNULA MARKET FOR ADULT (18-64), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 54 HIGH FLOW NASAL CANNULA MARKET FOR GERIATRIC (65+), BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 55 HIGH FLOW NASAL CANNULA MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 58 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 59 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 60 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 62 US: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 63 US: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 64 US: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 65 US: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 66 US: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 67 CANADA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 68 CANADA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 69 CANADA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 70 CANADA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 71 CANADA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 72 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 73 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 74 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 75 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 76 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 77 EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 78 GERMANY: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 79 GERMANY: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 80 GERMANY: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 81 GERMANY: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 82 GERMANY: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 83 FRANCE: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 84 FRANCE: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 85 FRANCE: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 86 FRANCE: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 87 FRANCE: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 88 UK: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 89 UK: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 90 UK: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 91 UK: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 92 UK: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 93 ITALY: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 94 ITALY: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 95 ITALY: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 ITALY: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 97 ITALY: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 98 SPAIN: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 SPAIN: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 100 SPAIN: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 SPAIN: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 102 SPAIN: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 103 REST OF EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 104 REST OF EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 105 REST OF EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 106 REST OF EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 107 REST OF EUROPE: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 114 JAPAN: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 115 JAPAN: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 116 JAPAN: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 JAPAN: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 118 JAPAN: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 119 CHINA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 CHINA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 121 CHINA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 CHINA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 123 CHINA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 124 INDIA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 125 INDIA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 126 INDIA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 INDIA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 128 INDIA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 129 AUSTRALIA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 AUSTRALIA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 131 AUSTRALIA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 AUSTRALIA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 133 AUSTRALIA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 134 SOUTH KOREA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 SOUTH KOREA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 136 SOUTH KOREA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 137 SOUTH KOREA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 138 SOUTH KOREA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 144 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 145 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 146 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 147 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 148 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 149 LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 150 BRAZIL: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 151 BRAZIL: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 152 BRAZIL: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 BRAZIL: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 154 BRAZIL: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 155 MEXICO: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 MEXICO: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 157 MEXICO: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 MEXICO: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 159 MEXICO: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 REST OF LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 164 REST OF LATIN AMERICA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 176 REST OF THE MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 REST OF THE MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY CONSUMABLES AND ACCESSORIES, 2024-2031 (USD MILLION)
  • TABLE 178 REST OF THE MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY PATIENT TYPE, 2024-2031 (USD MILLION)
  • TABLE 179 REST OF THE MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 180 REST OF THE MIDDLE EAST & AFRICA: HIGH FLOW NASAL CANNULA MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN HIGH FLOW NASAL CANNULA MARKET
  • TABLE 182 HIGH FLOW NASAL CANNULA MARKET: DEGREE OF COMPETITION
  • TABLE 183 HIGH FLOW NASAL CANNULA MARKET: REGION FOOTPRINT
  • TABLE 184 HIGH FLOW NASAL CANNULA MARKET: PRODUCT FOOTPRINT
  • TABLE 185 HIGH FLOW NASAL CANNULA MARKET: PATIENT TYPE FOOTPRINT
  • TABLE 186 HIGH FLOW NASAL CANNULA MARKET: APPLICATION FOOTPRINT
  • TABLE 187 HIGH FLOW NASAL CANNULA MARKET: END-USER FOOTPRINT
  • TABLE 188 HIGH FLOW NASAL CANNULA MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 189 HIGH FLOW NASAL CANNULA MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 190 HIGH FLOW NASAL CANNULA MARKET: DEALS, JANUARY 2021- AUGUST 2026
  • TABLE 191 FISHER & PAYKEL HEALTHCARE LIMITED: COMPANY OVERVIEW
  • TABLE 192 FISHER & PAYKEL HEALTHCARE LIMITED: PRODUCTS OFFERED
  • TABLE 193 VAPOTHERM: COMPANY OVERVIEW
  • TABLE 194 VAPOTHERM: PRODUCTS OFFERED
  • TABLE 195 VAPOTHERM: DEALS, JANUARY 2022- AUGUST 2026
  • TABLE 196 RESMED INC.: COMPANY OVERVIEW
  • TABLE 197 RESMED INC.: PRODUCTS OFFERED
  • TABLE 198 HAMILTON MEDICAL: COMPANY OVERVIEW
  • TABLE 199 HAMILTON MEDICAL: PRODUCTS OFFERED
  • TABLE 200 HAMILTON MEDICAL: EXPANSIONS, JANUARY 2022-AUGUST 2026
  • TABLE 201 DRAGERWERK AG & CO. KGAA: COMPANY OVERVIEW
  • TABLE 202 DRAGERWERK AG & CO. KGAA: PRODUCTS OFFERED
  • TABLE 203 INSPIRATION HEALTHCARE GROUP PLC: COMPANY OVERVIEW
  • TABLE 204 INSPIRATION HEALTHCARE GROUP PLC: PRODUCTS OFFERED
  • TABLE 205 MASIMO (DANAHER CORPORATION): COMPANY OVERVIEW
  • TABLE 206 MASIMO: PRODUCTS OFFERED
  • TABLE 207 MASIMO: DEALS, JANUARY 2022- AUGUST 2026
  • TABLE 208 VINCENT MEDICAL HOLDINGS LIMITED: COMPANY OVERVIEW
  • TABLE 209 VINCENT MEDICAL HOLDINGS LIMITED: PRODUCTS OFFERED
  • TABLE 210 FLEXICARE (GROUP) LIMITED: COMPANY OVERVIEW
  • TABLE 211 FLEXICARE (GROUP) LIMITED: PRODUCTS OFFERED
  • TABLE 212 MICOMME MEDICAL: COMPANY OVERVIEW
  • TABLE 213 MICOMME MEDICAL: PRODUCTS OFFERED
  • TABLE 214 BMC MEDICAL CO., LTD. COMPANY OVERVIEW
  • TABLE 215 BMC MEDICAL CO., LTD.: PRODUCTS OFFERED
  • TABLE 216 EAKIN HEALTHCARE: COMPANY OVERVIEW
  • TABLE 217 EAKIN HEALTHCARE: PRODUCTS OFFERED
  • TABLE 218 LOWENSTEIN MEDICAL SE & CO. KG: COMPANY OVERVIEW
  • TABLE 219 LOWENSTEIN MEDICAL SE & CO. KG: PRODUCTS OFFERED
  • TABLE 220 SHENZHEN COMEN MEDICAL INSTRUMENTS CO., LTD.: COMPANY OVERVIEW
  • TABLE 221 SHENZHEN COMEN MEDICAL INSTRUMENTS CO., LTD.: PRODUCTS OFFERED
  • TABLE 222 MEDLINE: COMPANY OVERVIEW
  • TABLE 223 MEDLINE: PRODUCTS OFFERED
  • TABLE 224 INTERSURGICAL LTD: COMPANY OVERVIEW
  • TABLE 225 RESPIRCARE MEDICAL: COMPANY OVERVIEW
  • TABLE 226 GREAT GROUP MEDICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 227 GALEMED CORPORATION: COMPANY OVERVIEW
  • TABLE 228 SILMAG S.A.: COMPANY OVERVIEW
  • TABLE 229 SALAERA LLC: COMPANY OVERVIEW
  • TABLE 230 TELESAIR, INC.: COMPANY OVERVIEW
  • TABLE 231 HEKA MEDICALS INDIA PVT. LTD.: COMPANY OVERVIEW
  • TABLE 232 BESMED HEALTH BUSINESS CORP.: COMPANY OVERVIEW
  • TABLE 233 CREATE BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 234 RESEARCH ASSUMPTIONS
  • TABLE 235 RISK ASSESSMENT: HIGH FLOW NASAL CANNULA MARKET

List of Figures

  • FIGURE 1 HIGH FLOW NASAL CANNULA MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 HIGH FLOW NASAL CANNULA MARKET: YEARS CONSIDERED
  • FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 4 GLOBAL HIGH FLOW NASAL CANNULA MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HIGH FLOW NASAL CANNULA MARKET
  • FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF HIGH FLOW NASAL CANNULA MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN HIGH FLOW NASAL CANNULA MARKET, 2026
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 9 RISING COPD, ASTHMA, AND RESPIRATORY FAILURE CASES TO DRIVE MARKET
  • FIGURE 10 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF HIGH FLOW NASAL CANNULA MARKET IN 2025
  • FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 12 NORTH AMERICA TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 13 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES
  • FIGURE 14 HIGH FLOW NASAL CANNULA MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 HIGH FLOW NASAL CANNULA MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 16 HIGH FLOW NASAL CANNULA MARKET SUPPLY CHAIN ANALYSIS
  • FIGURE 17 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING MANUFACTURING PHASE
  • FIGURE 18 HIGH FLOW NASAL CANNULA MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES IN HIGH FLOW NASAL CANNULA MARKET
  • FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN HIGH FLOW NASAL CANNULA MARKET, 2020-2023
  • FIGURE 21 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR HIGH FLOW NASAL CANNULA MARKET (JANUARY 2016-AUGUST 2026)
  • FIGURE 22 TOP PATENT APPLICANT COUNTRIES FOR HIGH FLOW NASAL CANNULA (JANUARY 2016- AUGUST 2026)
  • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
  • FIGURE 24 KEY BUYING CRITERIA FOR HIGH FLOW NASAL CANNULA SYSTEMS
  • FIGURE 25 NORTH AMERICA: HIGH FLOW NASAL CANNULA MARKET SNAPSHOT
  • FIGURE 26 ASIA PACIFIC: HIGH FLOW NASAL CANNULA MARKET SNAPSHOT
  • FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN HIGH FLOW NASAL CANNULA MARKET (2021-2025)
  • FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HIGH FLOW NASAL CANNULA MARKET (2025)
  • FIGURE 29 HIGH FLOW NASAL CANNULA MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 30 HIGH FLOW NASAL CANNULA MARKET: COMPANY FOOTPRINT
  • FIGURE 31 HIGH FLOW NASAL CANNULA MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 32 EV/EBITDA OF KEY VENDORS
  • FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDOR
  • FIGURE 34 HIGH FLOW NASAL CANNULA MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 35 FISHER & PAYKEL HEALTHCARE LIMITED: COMPANY SNAPSHOT (2026)
  • FIGURE 36 VAPOTHERM: COMPANY SNAPSHOT (2023)
  • FIGURE 37 RESMED INC.: COMPANY SNAPSHOT (2026)
  • FIGURE 38 DRAGERWERK AG & CO. KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 39 INSPIRATION HEALTHCARE GROUP PLC: COMPANY SNAPSHOT (2026)
  • FIGURE 40 VINCENT MEDICAL HOLDINGS LIMITED: COMPANY SNAPSHOT (2025)
  • FIGURE 41 RESEARCH DESIGN
  • FIGURE 42 PRIMARY SOURCES
  • FIGURE 43 BOTTOM-UP APPROACH
  • FIGURE 44 TOP-DOWN APPROACH
  • FIGURE 45 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 46 REVENUE SHARE ANALYSIS ILLUSTRATION: FISHER & PAYKEL HEALTHCARE
  • FIGURE 47 UPPLY-SIDE MARKET ESTIMATION: HIGH FLOW NASAL CANNULA MARKET (2025)
  • FIGURE 48 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 49 MARKET DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!